CKD
Advertisement
Effects of SGLT2 inhibitors on renal outcomes in patients with CKD, heart failure, and type 2 diabetes were examined.
A study examined whether urate-lowering therapy (ULT) for gout might help delay progression of chronic kidney disease (CKD).
A study compared hazard of progression to ESRD in patients with severe CKD who had partial or radical nephrectomy.
Researchers evaluated efficacy and safety of allopurinol versus febuxostat for gout in patients with stage 3 CKD.
Benefits of empagliflozin continued for a period after discontinuation but were lesser and seemed temporary.
Semaglutide reduced the risk of death among patients in the FLOW trial, who had CKD and type 2 diabetes.
FLOW trial data showed semaglutide safely reduced risks of major kidney outcomes regardless of CKD severity.
Drug stewardship to ensure the safety and effectiveness of medications is especially important in patients with CKD.
An analysis found that cases of CKD among women across the globe tripled in the past three decades.
A study examined the effects of semaglutide in patients with overweight/obesity and albuminuria CKD without T2D.
Previous research exploring an association between CKD and age-related macular degeneration has been inconclusive.
Researchers identified risk factors for nonconcordance with CKD screening and treatment guidelines in patients with diabetes.
A study examined whether restarting RASi after discontinuation would improve kidney outcomes.
Researchers sought to determine whether a higher salt intake was associated with chronic kidney disease (CKD).
Researchers estimated hyperkalemia incidence in patients with chronic kidney disease from routine clinical care.
ESSENTIAL assessed the safety and effectiveness of tolvaptan among patients in Korea with ADPKD and CKD stages 1 to 3.
A study examined the prevalence, patient characteristics, and medical management of patients with gout and CKD.
Researchers examined the long-term safety of oral hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia of CKD.
There is a gap in knowledge regarding the baseline risk of kidney disease in healthy patients with two APOL1 gene variants.
Under a new agreement with Akebia, US Renal Care will be able to prescribe Vafseo to dialysis patients with anemia of CKD.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.